WS
CTMX icon

Wedbush Securities’s CytomX Therapeutics CTMX Stock Holding History

Wedbush Securities’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,380
Closed -$198K – 998
2019
Q1 		$198K Sell
18,380
-6,975
-28% -$103K 0.02% 777
2018
Q4 		$383K Buy
25,355
+1,900
+8% +$28.2K 0.05% 450
2018
Q3 		$434K Buy
23,455
+10,225
+77% +$233K 0.05% 451
2018
Q2 		$302K Buy
+13,230
New +$338K 0.04% 549

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wedbush Securities's CTMX Position: Q2 2019 in Review

Wedbush Securities sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 18,380 shares — an estimated $198K sold.

Wedbush Securities first reported a position in CTMX in Q2 2018 and held it in 4 quarters. The position peaked at $434K in Q3 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Wedbush Securities reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wedbush Securities sold 18,380 CytomX Therapeutics shares in Q2 2019, an estimated $198K.
  • Wedbush Securities first reported a position in CytomX Therapeutics in Q2 2018 and held it in 4 quarters.
  • Wedbush Securities's CytomX Therapeutics position peaked at $434K in Q3 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Wedbush Securities's 13F filing for Q2 2019, filed 1 Aug 2019.